Live Breaking News & Updates on Tom Bishop Bi Research Analyst
Stay updated with breaking news from Tom bishop bi research analyst. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Christopher Missling [Audio gap] the quest for disease-confined therapies for neurodegenerative disorders. Separately, the independent Data Monitoring Safety Board, DSMB, also like the ongoing clinical trial program, including the late-stage AVATAR RS-002, EXCELLENCE RS-003, and the US Rett syndrome extension study, RS-EP-001 of Anavex 2-73 has also completed its recent pre-planned review of the respective interim safety data for these three separate clinical studies. Upon review of the interim safety data, the DSMB made the following recommendation for each of the three studies. The DSMB recommendation is to continue the studies without modifications. This is very good news and indicates we re on the right path with all these studies. As a reminder, our clinical strategy is to clearly differentiate from other biopharma companies and clinical studies in CNS. Anavex is continuing to pioneer the approach of big data, including Anavex in clinical trials to leverage the level ....
Operator Good afternoon. My name is Erin, and I will be your conference call operator today. Welcome to the Anavex Life Sciences fiscal 2021 first-quarter conference call. As a reminder, this conference call is being recorded. I would now like to introduce your host for today s conference, Clint Tomlinson. Sir, go ahead. Clint Tomlinson Investor Relations Thank you, and good afternoon, everyone. We appreciate you joining us today for Anavex Life Sciences conference call and webcast. Our agenda is to review the company s financial results for the first quarter of its fiscal 2021 financial year and provide clinical study and business update. A taped replay of this call will be available approximately two hours after the call s conclusion and will remain available for one month. ....